Back

Analysts reaffirm Buy ratings on Ascendis Pharma, Cytokinetics with targets of $273 and $105

Verifying
  • Morgan Stanley and Wells Fargo maintained Buy ratings on Ascendis Pharma and Cytokinetics.
  • Ascendis targets $273 and Cytokinetics targets $105, versus $227.87 and $65.60 closes.
  • Cantor Fitzgerald and Needham separately maintained Buy ratings on Sept. 25 and Sept. 29.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.